• Citer

Adapting radiation therapy to immunotherapy: Delineation and treatment planning of pre-operative immune-modulating breast iSBRT in 151 patients treated in the randomized phase II Neo-CheckRay trial.

par De Caluwé, A;Bellal, Selma ;Cao, Kim-Anh Lê;Peignaux, Karine;Remouchamps, Vincent;Baten, A;Longton, Eléonore;Bessieres, Igor;Vu-Bezin, Jérémi;Kirova, Youlia;Gestel, D Van;Desmoulins, Isabelle;Ignatiadis, M;Romano, E;Buisseret, Laurence ;Piccart, M;Vandekerkhove, Christophe;Gulyban, A;Poortmans, P
Référence Radiotherapy and oncology, 206, page (110836)
Publication Publié, 2025-05-01

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Résumé :

The randomized multicentric phase II Neo-CheckRay trial investigated preoperative immune-modulating stereotactic body radiation therapy (iSBRT) 8 Gy x 3 fractions in combination with chemotherapy with or without the anti PD-L1 durvalumab and the anti-CD73 oleclumab in early-stage, high-risk, luminal B breast cancer. iSBRT was solely delivered to the primary breast cancer leveraging on its immune modulating potential to sustain an anti-tumour response. To avoid immunosuppression induced by radiation therapy (RT), the tumour draining lymph nodes (TDLN) were spared. Here, we present the constraints used in the Neo-CheckRay trial and a dosimetric analysis of all delivered treatment plans with a special focus on the dose to the TDLN.